参考文献/References:
[1]Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA A Cancer J Clin,2021,71(3):209-249.[2]Mauri G,Bonazzina E,Amatu A,et al.The evolutionary landscape of treatment for BRAFV600Emutant metastatic colorectal cancer[J].Cancers (Basel),2021,13(1):E137.[3]Ruffinelli JC,Santos Vivas C,Sanz-Pamplona R,et al.New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients[J].Expert Rev Gastroenterol Hepatol,2021,15(1):65-79.[4]Luo QX,Chen DK,Fan XJ,et al.KRAS and PIK3CA bi-mutations predict a poor prognosis in colorectal cancer patients: a single-site report[J].Transl Oncol,2020,13(12):100874.[5]Tao ZQ,Shi AM,Li R,et al.Microarray bioinformatics in cancer- a review[J].J BUON,2017,22(4):838-843.[6]Saito M,Momma T,Kono K.Targeted therapy according to next generation sequencing-based panel sequencing[J].Fukushima J Med Sci,2018,64(1):9-14.[7]Harada K,Okamoto W,Mimaki S,et al.Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy[J].BMC Cancer,2019,19(1):255.[8]Zhao B,Baloch Z,Ma YH,et al.Identification of potential key genes and pathways in early-onset colorectal cancer through bioinformatics analysis[J].Cancer Control,2019,26(1):1073274819831260.[9]Cojocneanu R,Braicu C,Raduly L,et al.Plasma and tissue specific miRNA expression pattern and functional analysis associated to colorectal cancer patients[J].Cancers (Basel),2020,12(4):E843.[10]Kishore C,Bhadra P.Current advancements and future perspectives of immunotherapy in colorectal cancer research[J].Eur J Pharmacol,2021,893:173819.[11]Wu J,Cai JT.Dilemma and challenge of immunotherapy for pancreatic cancer[J].Dig Dis Sci,2021,66(2):359-368.[12]Chakravarty D,Huang L,Kahn M,et al.Immunotherapy for metastatic prostate cancer: current and emerging treatment options[J].Urol Clin North Am,2020,47(4):487-510.[13]Esteva FJ,Hubbard-Lucey VM,Tang J,et al.Immunotherapy and targeted therapy combinations in metastatic breast cancer[J].Lancet Oncol,2019,20(3):e175-e186.[14]Lei X,Lei Y,Li JK,et al.Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy[J].Cancer Lett,2020,470:126-133. [15]Edgar R,Domrachev M,Lash AE.Gene Expression Omnibus: NCBI gene expression and hybridization array data repository[J].Nucleic Acids Res,2002,30(1):207-210.[16]Wang ZN,Jensen MA,Zenklusen JC.A practical guide to the cancer genome atlas (TCGA) [J].Methods Mol Biol,2016,1418:111-141.[17]Kanehisa M.The KEGG database[J].Novartis Found Symp,2002,247:91-252.[18]Ashburner M,Ball CA,Blake JA,et al.Gene ontology: tool for the unification of biology. The Gene Ontology Consortium[J].Nat Genet,2000,25(1):25-29.[19]Tang ZF,Li CW,Kang BX,et al.GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J].Nucleic Acids Res,2017,45(W1):W98-W102.[20]Uhlen M,Zhang C,Lee S,et al.A pathology atlas of the human cancer transcriptome[J].Science,2017,357(6352):eaan2507. [21]Subramanian A,Tamayo P,Mootha VK,et al.Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles[J].Proc Natl Acad Sci U S A,2005,102(43):15545-15550.[22]Hristova VA,Chan DW.Cancer biomarker discovery and translation: proteomics and beyond[J].Expert Rev Proteomics,2019,16(2):93-103.[23]Lu MX,Zhang JX,Zhang LJ.Emerging concepts and methodologies in cancer biomarker discovery[J].Crit Rev Oncog,2017,22(5-6):371-388.[24]Ganesh K,Stadler ZK,Cercek A,et al.Immunotherapy in colorectal cancer: rationale, challenges and potential[J].Nat Rev Gastroenterol Hepatol,2019,16(6):361-375.[25]Johdi NA,Sukor NF.Colorectal cancer immunotherapy: options and strategies[J].Front Immunol,2020,11:1624.[26]Cicatiello AG,Ambrosio R,Dentice M.Thyroid hormone promotes differentiation of colon cancer stem cells[J].Mol Cell Endocrinol,2017,459:84-89.[27]Tian D,Tian M,Han G,et al.Increased glucocorticoid receptor activity and proliferation in metastatic colon cancer[J].Sci Rep,2019,9(1):11257.[28]Deng D,Luo X,Zhang SF,et al.Immune cell infiltration-associated signature in colon cancer and its prognostic implications[J].Aging (Albany NY),2021,13(15):19696-19709.[29]Malka D,Lièvre A,André T,et al.Immune scores in colorectal cancer: where are we? [J].Eur J Cancer,2020,140:105-118.[30]Abdul-Latif M,Townsend K,Dearman C,et al.Immunotherapy in gastrointestinal cancer: the current scenario and future perspectives[J].Cancer Treat Rev,2020,88:102030.[31]Xie P,Mo JL,Liu JH,et al.Pharmacogenomics of 5-fluorouracil in colorectal cancer: review and update[J].Cell Oncol (Dordr),2020,43(6):989-1001.[32]Blondy S,David V,Verdier M,et al.5-Fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes[J].Cancer Sci,2020,111(9):3142-3154.[33]Wassenaar TM.E. coli and colorectal cancer: a complex relationship that deserves a critical mindset[J].Crit Rev Microbiol,2018,44(5):619-632.[34]Tang L,Zhou YJ,Zhu SL,et al.E. coli diversity: low in colorectal cancer[J].BMC Med Genomics,2020,13(1):59.[35]Mo A,Jackson S,Varma K,et al.Distinct transcriptional changes and epithelial-stromal interactions are altered in early-stage colon cancer development[J].Mol Cancer Res,2016,14(9):795-804.[36]Liu JH,Jiang CH,Xu CJ,et al.Identification and development of a novel invasion-related gene signature for prognosis prediction in colon adenocarcinoma[J].Cancer Cell Int,2021,21(1):101.[37]Liang B,Zheng B,Zhou Y,et al.Characterization of a tumor-microenvironment-relevant gene set based on tumor severity in colon cancer and evaluation of its potential for dihydroartemisinintargeting[J].Evid Based Complement Alternat Med,2021,2021:4812068.[38]Hardbower DM,Coburn LA,Asim M,et al.EGFR-mediated macrophage activation promotes colitis-associated tumorigenesis[J].Oncogene,2017,36(27):3807-3819.[39]Edin S,Kaprio T,Hagstr?觟m J,et al.The prognostic importance of CD20+ B lymphocytes in colorectal cancer and the relation to other immune cell subsets[J].Sci Rep,2019,9(1):19997.[40]Saito T,Nishikawa H,Wada H,et al.Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers[J].Nat Med,2016,22(6):679-684.[41]O’Malley G,Treacy O,Lynch K,et al.Stromal Cell PD-L1 Inhibits CD8+ T-cell Antitumor Immune Responses and Promotes Colon Cancer[J].Cancer Immunol Res,2018,6(11):1426-1441. [42]Olesch C,Sirait-Fischer E,Berkefeld M,et al.S1PR4 ablation reduces tumor growth and improves chemotherapy via CD8+ T cell expansion[J].J Clin Invest,2020,130(10):5461-5476.[43]Mizuno R,Kawada K,Itatani Y,et al.The role of tumor-associated neutrophils in colorectal cancer[J].Int J Mol Sci,2019,20(3):E529.[44]Locati M,Curtale G,Mantovani A.Diversity, mechanisms, and significance of macrophage plasticity[J].Annu Rev Pathol,2020,15:123-147.[45]Isidro RA,Appleyard CB.Colonic macrophage polarization in homeostasis, inflammation, and cancer[J].Am J PhysiolGastrointest Liver Physiol,2016,311(1):G59-G73.[46]Najafi M,Hashemi Goradel N,Farhood B,et al.Macrophage polarity in cancer: A review[J].J Cell Biochem,2019,120(3):2756-2765.
相似文献/References:
[1]苏周荣,杜东霖,魏正强.左半结肠癌伴梗阻一期切除吻合策略研究[J].医学信息,2018,31(10):51.[doi:10.3969/j.issn.1006-1959.2018.10.016]
SU Zhou-rong,DU Dong-lin,WEI Zheng-qiang.Strategy of One-stage Resection and Anastomosis for Left Colon Cancer with Obstruction[J].Medical Information,2018,31(10):51.[doi:10.3969/j.issn.1006-1959.2018.10.016]
[2]石 磊,孙新增,李宝山,等.Ⅱ、Ⅲ期结肠癌患者辅助化疗XELOX方案、FOLFOX方案的临床疗效、不良反应及生活质量对比[J].医学信息,2018,31(13):68.[doi:10.3969/j.issn.1006-1959.2018.13.020]
SHI Lei,SUN Xin-zeng,LI Bao-shan,et al.Clinical Efficacy,Adverse Reactions and Quality of Life of Adjuvant Chemotherapy XELOX and FOLFOX in Patients with Stage II and III Colon Cancer[J].Medical Information,2018,31(10):68.[doi:10.3969/j.issn.1006-1959.2018.13.020]
[3]王 超,范小华,张 力,等.下腔静脉畸形伴腹腔多脏器异位合并结肠癌1例[J].医学信息,2018,31(18):188.[doi:10.3969/j.issn.1006-1959.2018.18.062]
WANG Chao,FAN Xiao-hua,ZHANG Li,et al.a Case of Inferior Vena Cava Malformation Associated with Multiple Abdominal Organ Ectopic Colon Cancer[J].Medical Information,2018,31(10):188.[doi:10.3969/j.issn.1006-1959.2018.18.062]
[4]操利超,张核子,余晨笛,等.CLDN11在结肠癌中的预后价值及其作为潜在免疫治疗靶点的研究[J].医学信息,2022,35(14):10.[doi:10.3969/j.issn.1006-1959.2022.14.002]
CAO Li-chao,ZHANG He-zi,YU Chen-di,et al.The Prognostic Value of CLDN11 in Colon Cancer and its Potential Immunotherapy Targets[J].Medical Information,2022,35(10):10.[doi:10.3969/j.issn.1006-1959.2022.14.002]
[5]黄富全.结合靶向药物综合治疗结肠癌肝及肝外转移术后7年1例报告[J].医学信息,2019,32(01):186.[doi:10.3969/j.issn.1006-1959.2019.01.061]
[6]葛菁茹,朱静雅,苏日新,等.以肺转移为首发表现的结肠癌预后分析[J].医学信息,2021,34(04):96.[doi:10.3969/j.issn.1006-1959.2021.04.025]
GE Jing-ru,ZHU Jing-ya,SU Ri-xin,et al.Prognostic Analysis of Colon Cancer with Lung Metastasis as the First Manifestation[J].Medical Information,2021,34(10):96.[doi:10.3969/j.issn.1006-1959.2021.04.025]
[7]韩 猛,薛三宝,倪 丰.CT与MRI术前诊断结肠癌及评价术后复发的价值[J].医学信息,2021,34(21):175.[doi:10.3969/j.issn.1006-1959.2021.21.050]
HAN Meng,XUE San-bao,NI Feng.Value of CT and MRI in Preoperative Diagnosis and Postoperative Recurrence of Colon Cancer[J].Medical Information,2021,34(10):175.[doi:10.3969/j.issn.1006-1959.2021.21.050]
[8]操利超,巴 颖,卢晓萍,等.基于TCGA和GEO数据库构建结肠癌预后模型[J].医学信息,2021,34(24):27.[doi:10.3969/j.issn.1006-1959.2021.24.006]
CAO Li-chao,BA Ying,LU Xiao-ping,et al.Prognostic Model of Colon Cancer Based on TCGA and GEO Database[J].Medical Information,2021,34(10):27.[doi:10.3969/j.issn.1006-1959.2021.24.006]
[9]张秀娟,黄丽娟.mTOR、PTEN、Ki-67蛋白表达水平变化与结肠癌病理学特征的相关性分析[J].医学信息,2022,35(19):54.[doi:10.3969/j.issn.1006-1959.2022.19.014]
ZHANG Xiu-juan,HUANG Li-juan.Correlation of mTOR, PTEN and Ki-67 Protein Expression with Pathological Features of Colon Cancer[J].Medical Information,2022,35(10):54.[doi:10.3969/j.issn.1006-1959.2022.19.014]
[10]李 洋.北京市海淀区居民结肠癌防治知识知晓情况分析[J].医学信息,2021,34(08):141.[doi:10.3969/j.issn.1006-1959.2021.08.037]
LI Yang.Analysis of Knowledge About Colon Cancer Prevention and Treatment Among Residents in Haidian District,Beijing[J].Medical Information,2021,34(10):141.[doi:10.3969/j.issn.1006-1959.2021.08.037]